Physician profile
David A Davis
NPI 1124024880
$920.36
in general payments reported to CMS, 2019-2025
14 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $12.99 · 2021: $131 · 2022: $46.26 · 2023: $149 · 2024: $222 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $190.92 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $132.79 | 2023-2025 | |
| Abbvie INC. | $105.84 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.06 | 2021 | |
| Amgen INC. | $72.50 | 2019-2023 | Otezla |
| Galderma Laboratories, L.P. | $66.89 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $58.97 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $37.53 | 2023-2024 | |
| Ucb, INC. | $37.40 | 2024 | Bimzelx |
| Genentech USA, INC. | $28.09 | 2022 | |
| Celgene Corporation | $24.12 | 2019 | |
| Biofrontera INC. | $22.33 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.64 | 2024 | |
| Organon LLC | $20.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.